BRAF and neoplasm: Overall, these data suggest that MAPK inhibition can lead to dependence on MCL-1 in vivo and that therapeutic targeting using BRAF and MCL-1 inhibitors can induce profound tumor (in some cases pathologic complete responses) in tumor-bearing mice.